Literature DB >> 34697068

OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation.

Ricuphan Khamko1,2, Jureerut Daduang2, Chatri Settasatian3, Temduang Limpaiboon4,5.   

Abstract

BACKGROUND/AIM: Opioid-binding protein/cell adhesion molecule-like (OPCML) plays a crucial role in the suppression of tumor progression in several cancer types. Nevertheless, the association between OPCML functions and cholangiocarcinoma (CCA) progression remains unknown. We aimed to investigate biological functions of OPCML and related signaling pathways in CCA cell lines.
MATERIALS AND METHODS: Methylation status and ectopic expression of OPCML were determined in CCA cell lines using methylation-specific polymerase chain reaction and pcDNA3.1+/C-(K)DYK-OPCML, respectively. Cell proliferation, migration and invasion were investigated.
RESULTS: OPCML was found to be epigenetically silenced by DNA methylation. Ectopic expression of OPCML inhibited CCA proliferation by inducing apoptosis via AXL receptor tyrosine kinase/signal transducer and activator of transcription 3 (AXL/STAT3) inactivation. It also suppressed cell migration and invasion via down-regulation of Rho GTPases, ras homolog family member A (RHOA), Rac family small GTPase 1 (RAC1) and cell division cycle 42 (CDC42).
CONCLUSION: We are the first to unravel the antitumor effects and the related signaling pathways of OPCML in CCA. The loss of OPCML expression due to promoter hypermethylation can cause a decrease in cell death but increase in cell migration and invasion, which may at least in part contribute to CCA progression. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AXL/STAT3 signaling; OPCML; RHOA/RAC1/CDC42; methylation

Mesh:

Substances:

Year:  2021        PMID: 34697068      PMCID: PMC8569815          DOI: 10.21873/cgp.20296

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  40 in total

1.  Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.

Authors:  Sara Duarte-Pereira; Filipa Paiva; Vera Lúcia Costa; João Ramalho-Carvalho; Joana Savva-Bordalo; Angelo Rodrigues; Franclim Ricardo Ribeiro; Vitor M Silva; Jorge Oliveira; Rui Henrique; Carmen Jerónimo
Journal:  Eur J Cancer       Date:  2011-01-25       Impact factor: 9.162

2.  OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling.

Authors:  Chunhong Li; Liping Tang; Lijuan Zhao; Lili Li; Qian Xiao; Xinrong Luo; Weiyan Peng; Guosheng Ren; Qian Tao; Tingxiu Xiang
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 3.  The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.

Authors:  Rocio I R Macias; Jesus M Banales; Bruno Sangro; Jordi Muntané; Matias A Avila; Elisa Lozano; Maria J Perugorria; Francisco J Padillo; Luis Bujanda; Jose J G Marin
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-08-04       Impact factor: 5.187

4.  A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading.

Authors:  T Nakajima; Y Kondo; M Miyazaki; K Okui
Journal:  Hum Pathol       Date:  1988-10       Impact factor: 3.466

5.  Expression of seven main Rho family members in gastric carcinoma.

Authors:  Yanglin Pan; Feng Bi; Na Liu; Yan Xue; Xuebiao Yao; Yi Zheng; Daiming Fan
Journal:  Biochem Biophys Res Commun       Date:  2004-03-12       Impact factor: 3.575

6.  OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma.

Authors:  Feng Ye; Song-Fa Zhang; Xing Xie; Wei-Guo Lu
Journal:  Cancer Invest       Date:  2008-07       Impact factor: 2.176

7.  Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.

Authors:  Xiangbin Xing; Weibin Cai; Sanmei Ma; Yongfei Wang; Huijuan Shi; Ming Li; Jinxia Jiao; Yang Yang; Longshan Liu; Xiangliang Zhang; Minhu Chen
Journal:  BMC Cancer       Date:  2017-04-14       Impact factor: 4.430

Review 8.  Risk Factors for Cholangiocarcinoma in Thailand: A Systematiczzm321990Review and Meta-Analysis

Authors:  Siriporn Kamsa-ard; Supot Kamsa-ard; Vor Luvira; Krittika Suwanrungruang; Patravoot Vatanasapt; Surapon Wiangnon
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

9.  The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

Authors:  Arthur B McKie; Sebastian Vaughan; Elisa Zanini; Imoh S Okon; Louay Louis; Camila de Sousa; Mark I Greene; Qiang Wang; Roshan Agarwal; Dmitry Shaposhnikov; Joshua L C Wong; Hatice Gungor; Szymon Janczar; Mona El-Bahrawy; Eric W-F Lam; Naomi E Chayen; Hani Gabra
Journal:  Cancer Discov       Date:  2012-02       Impact factor: 39.397

10.  OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.

Authors:  Yan Cui; Ying Ying; Andrew van Hasselt; Ka Man Ng; Jun Yu; Qian Zhang; Jie Jin; Dingxie Liu; Johng S Rhim; Sun Young Rha; Myriam Loyo; Anthony T C Chan; Gopesh Srivastava; George S W Tsao; Grant C Sellar; Joseph J Y Sung; David Sidransky; Qian Tao
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  1 in total

1.  Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.

Authors:  Ricuphan Khamko; Wiphawan Wasenang; Jureerut Daduang; Chatri Settasatian; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.